Akebia Therapeutics (AKBA) Long-Term Investments (2015 - 2018)
Akebia Therapeutics (AKBA) posted quarterly Long-Term Investments of $245000.0 for Q4 2018, down 99.51% quarter-over-quarter from $49.6 million in Q4 2015.
Akebia Therapeutics (AKBA) Long-Term Investments (2015 - 2018) Analysis & Trends
Akebia Therapeutics (AKBA) has reported Long-Term Investments for 2 consecutive years, with $245000.0 the latest figure, recorded in Q4 2018.
- In Q4 2018, Long-Term Investments changed N/A year-over-year to $245000.0; the TTM figure through Dec 2018 stood at $245000.0 (changed N/A YoY), while the FY2018 annual figure was $245000.0, changed N/A from the prior year.
- Long-Term Investments eased to $245000.0 in Q4 2018 per AKBA's latest filing, from $49.6 million in the prior quarter.
- Across five years, Long-Term Investments topped out at $51.0 million in Q3 2015 and bottomed at $245000.0 in Q4 2018.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Long-Term Investments (Qtr) |
|---|---|---|---|---|---|
| 1 | Haleon | 43.91 Bn | 42.95 Bn | - | 92.58 Mn |
| 2 | Teva Pharmaceutical Industries | 43.15 Bn | 39.49 Bn | 2.15 Bn | - |
| 3 | Zoetis | 31.52 Bn | 29.84 Bn | 1.05 Bn | - |
| 4 | Takeda Pharmaceutical | 28.58 Bn | 22.78 Bn | 5.10 Bn | 63.23 Mn |
| 5 | United Therapeutics | 22.16 Bn | 19.50 Bn | 683.80 Mn | 1.14 Bn |
| 6 | Viatris | 18.76 Bn | 17.87 Bn | 1.46 Bn | - |
| 7 | Neurocrine Biosciences | 15.48 Bn | 15.09 Bn | 935.80 Mn | 149.10 Mn |
| 8 | Elanco Animal Health | 11.69 Bn | 11.16 Bn | 798.00 Mn | - |
| 9 | Dr Reddys Laboratories | 10.13 Bn | 9.96 Bn | - | 60.00 Mn |
| 10 | Akebia Therapeutics | 247.98 Mn | 92.43 Mn | 38.70 Mn | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Dec 31, 2018 | 245,000.00 |
| Dec 31, 2015 | 49.60 Mn |
| Sep 30, 2015 | 50.97 Mn |
| Jun 30, 2015 | 38.76 Mn |
| Mar 31, 2015 | 33.10 Mn |